{"entity":{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","aka":[],"tldr":"Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.","summary":"Autologous CAR-T, TIL and TCR-T are one-batch-per-patient manufacturing: leukapheresis, shipping, transduction, expansion, release testing and return take several weeks, during which some patients progress or die, a proportion of products fail specification, and list prices run to several hundred thousand dollars before hospital costs. Only a small fraction of eligible patients receive approved CAR-T because of slot availability, referral and cost. Radioligand therapy has a different supply problem: lutetium-177 depends on a handful of reactors and enrichment sources, and actinium-225 for alpha therapy has been limited to a few curies a year worldwide from thorium-229 stocks, with accelerator and thorium-based production only now scaling. ADCs and bispecifics have complex biologics supply chains with a small number of contract manufacturers. In vivo CAR generation, allogeneic products, point-of-care and automated manufacturing, and new isotope production routes are the technical answers.","asOf":"2026-09-08","links":[{"label":"Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)","url":"https://doi.org/10.1001/jamaoncol.2018.0977"},{"label":"Maude et al., Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia (ELIANA, NEJM 2018)","url":"https://doi.org/10.1056/NEJMoa1709866"},{"label":"US Department of Energy Isotope Program","url":"https://www.isotopes.gov/"}],"tags":[],"related":["radiopharma-roadmap","idea-reg-legacy-radium-recovery-ac225","idea-reg-ac225-accelerator-pharmacopoeia","idea-reg-yb176-enrichment-capacity","idea-reg-medical-isotope-reactor-reserve","idea-reg-alpha-emitter-portfolio","idea-reg-regional-radiopharmacy-hubs","idea-reg-isotope-supply-observatory","lu-177","ac-225"],"indications":["dlbcl","prostate","neuroendocrine"],"sections":[],"technologies":["radioligand-therapy","targeted-alpha-therapy"],"targets":[],"drugs":["pluvicto","lutathera","ac225-psma"],"companies":["novartis","terrapower-isotopes","orano-med","itm","curium"],"institutions":[],"pathways":[],"terms":["alpha-vs-beta","dosimetry","theranostics"],"trials":["vision"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"stage":"regulation-manufacturing","severity":"major","metrics":[{"label":"Estimated total cost of CAR-T therapy including list price and management of adverse events (2018 US analysis)","value":"Up to ~US$500,000 per patient","source":"Hernandez, Prasad & Gellad, JAMA Oncology 2018","url":"https://doi.org/10.1001/jamaoncol.2018.0977"},{"label":"Patients in ELIANA for whom tisagenlecleucel could not be manufactured","value":"7 of 92 enrolled","source":"Maude et al., NEJM 2018","url":"https://doi.org/10.1056/NEJMoa1709866"},{"label":"Historic global actinium-225 supply from thorium-229 stockpiles","value":"~63 GBq (1.7 Ci) per year","source":"Robertson et al., Current Radiopharmaceuticals 2018","url":"https://doi.org/10.2174/1874471011666180416161908"}],"causes":["Autologous products are bespoke batches with no economies of scale.","Viral vector and GMP capacity are limited and expensive.","Actinium-225 has historically come only from decay of legacy thorium-229 held by a few government laboratories.","Lutetium-177 production depends on reactor time and enriched target material from few suppliers.","Release testing, cold-chain logistics and hospital accreditation add weeks and cost that no design optimisation removes."],"currentEfforts":["Umoja, Interius and Orna are developing in vivo CAR-T that programmes T cells inside the patient, removing manufacturing entirely.","Allogene, Caribou, Sana and Fate build off-the-shelf allogeneic CAR-T and CAR-NK products from healthy donor or iPSC sources.","Novartis' T-Charge and point-of-care manufacturing programmes at academic centres cut vein-to-vein time to days.","The US Department of Energy Isotope Program is producing accelerator-based actinium-225, and TerraPower Isotopes and Orano Med are scaling thorium-derived and accelerator-based supply.","ITM and Curium have expanded non-carrier-added lutetium-177 production, and Novartis has built dedicated radioligand plants.","Automated closed-system cell manufacturing platforms (for example, Miltenyi CliniMACS Prodigy and Lonza Cocoon) reduce labour and cleanroom needs."],"successLooksLike":"A CAR-T or equivalent cell therapy is available within a week of decision at a cost comparable to a course of biologic therapy, the majority of eligible patients actually receive it, and isotope supply is no longer the limiting factor for any approved radioligand."},"route":"/bottlenecks/b-manufacturing-cell-therapy/","neighbours":{"roadmap":[{"id":"radiopharma-roadmap","kind":"roadmap","name":"Radiopharmaceutical roadmap: iodine → lutetium → actinium","route":"/roadmaps/radiopharma-roadmap/"}],"idea":[{"id":"idea-reg-medical-isotope-reactor-reserve","kind":"idea","name":"A coordinated reserve and shared schedule for the world's medical isotope reactors","route":"/ideas/idea-reg-medical-isotope-reactor-reserve/"},{"id":"idea-reg-isotope-supply-observatory","kind":"idea","name":"A global medical isotope supply observatory with forecasts and shortage alerts","route":"/ideas/idea-reg-isotope-supply-observatory/"},{"id":"idea-fund-academic-radiopharma-pipeline","kind":"idea","name":"A university cyclotron network with shared regulatory files for new tracers","route":"/ideas/idea-fund-academic-radiopharma-pipeline/"},{"id":"idea-reg-yb176-enrichment-capacity","kind":"idea","name":"Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier","route":"/ideas/idea-reg-yb176-enrichment-capacity/"},{"id":"idea-reg-alpha-emitter-portfolio","kind":"idea","name":"Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211","route":"/ideas/idea-reg-alpha-emitter-portfolio/"},{"id":"idea-reg-legacy-radium-recovery-ac225","kind":"idea","name":"Recover legacy radium-226 sources worldwide as the feedstock for actinium-225","route":"/ideas/idea-reg-legacy-radium-recovery-ac225/"},{"id":"idea-reg-ac225-accelerator-pharmacopoeia","kind":"idea","name":"Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit","route":"/ideas/idea-reg-ac225-accelerator-pharmacopoeia/"},{"id":"idea-reg-regional-radiopharmacy-hubs","kind":"idea","name":"Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes","route":"/ideas/idea-reg-regional-radiopharmacy-hubs/"}],"isotope":[{"id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/"},{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"}],"indication":[{"id":"dlbcl","kind":"indication","name":"Diffuse large B-cell lymphoma","route":"/indications/dlbcl/"},{"id":"neuroendocrine","kind":"indication","name":"Neuroendocrine tumours","route":"/indications/neuroendocrine/"},{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"}],"technology":[{"id":"actinium-225-supply","kind":"technology","name":"Actinium-225 supply: thorium stocks, accelerators and radium targets","route":"/technologies/actinium-225-supply/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"},{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/"},{"id":"research-reactor-isotope-production","kind":"technology","name":"Research reactors for medical isotopes (Mo-99, Lu-177, I-131)","route":"/technologies/research-reactor-isotope-production/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"drug":[{"id":"ac225-psma","kind":"drug","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}],"company":[{"id":"curium","kind":"company","name":"Curium","route":"/companies/curium/"},{"id":"itm","kind":"company","name":"ITM Isotope Technologies Munich","route":"/companies/itm/"},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"},{"id":"orano-med","kind":"company","name":"Orano Med","route":"/companies/orano-med/"},{"id":"terrapower-isotopes","kind":"company","name":"TerraPower Isotopes","route":"/companies/terrapower-isotopes/"}],"term":[{"id":"alpha-vs-beta","kind":"term","name":"Alpha vs beta emitters","route":"/terms/alpha-vs-beta/"},{"id":"dosimetry","kind":"term","name":"Dosimetry","route":"/terms/dosimetry/"},{"id":"theranostics","kind":"term","name":"Theranostics","route":"/terms/theranostics/"}],"trial":[{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/"}],"bottleneck":[{"id":"b-ac225-supply","kind":"bottleneck","name":"Actinium-225 supply","route":"/bottlenecks/b-ac225-supply/"}]}}